BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 26937656)

  • 1. Immune Responses to the Cancer Testis Antigen XAGE-1b in Non Small Cell Lung Cancer Caucasian Patients.
    Saito K; Nakayama E; Valmori D
    PLoS One; 2016; 11(3):e0150623. PubMed ID: 26937656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients.
    Ohue Y; Eikawa S; Okazaki N; Mizote Y; Isobe M; Uenaka A; Fukuda M; Old LJ; Oka M; Nakayama E
    Int J Cancer; 2012 Sep; 131(5):E649-58. PubMed ID: 22109656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational prediction of vaccine potential epitopes and 3-dimensional structure of XAGE-1b for non-small cell lung cancer immunotherapy.
    Tarek MM; Shafei AE; Ali MA; Mansour MM
    Biomed J; 2018 Apr; 41(2):118-128. PubMed ID: 29866600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.
    Zhou Q; Guo AL; Xu CR; An SJ; Wang Z; Yang SQ; Wu YL
    Clin Exp Immunol; 2008 Sep; 153(3):392-400. PubMed ID: 18803763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells.
    Shimono M; Uenaka A; Noguchi Y; Sato S; Okumura H; Nakagawa K; Kiura K; Tanimoto M; Nakayama E
    Int J Oncol; 2007 Apr; 30(4):835-40. PubMed ID: 17332921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma.
    Talebian Yazdi M; Loof NM; Franken KL; Taube C; Oostendorp J; Hiemstra PS; Welters MJ; van der Burg SH
    Cancer Immunol Immunother; 2015 Sep; 64(9):1109-21. PubMed ID: 26025564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens.
    Kikuchi E; Yamazaki K; Nakayama E; Sato S; Uenaka A; Yamada N; Oizumi S; Dosaka-Akita H; Nishimura M
    Cancer Immun; 2008 Aug; 8():13. PubMed ID: 18752338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. XAGE-1 expression in non-small cell lung cancer and antibody response in patients.
    Nakagawa K; Noguchi Y; Uenaka A; Sato S; Okumura H; Tanaka M; Shimono M; Ali Eldib AM; Ono T; Ohara N; Yoshino T; Yamashita K; Tsunoda T; Aoe M; Shimizu N; Nakayama E
    Clin Cancer Res; 2005 Aug; 11(15):5496-503. PubMed ID: 16061866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic variants of immunoglobulin γ and κ chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer.
    Pandey JP; Namboodiri AM; Ohue Y; Oka M; Nakayama E
    Clin Exp Immunol; 2014 Apr; 176(1):78-83. PubMed ID: 24304136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoscreening of a cDNA library from a lung cancer cell line using autologous patient serum: Identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma.
    Ali Eldib AM; Ono T; Shimono M; Kaneko M; Nakagawa K; Tanaka R; Noguchi Y; Nakayama E
    Int J Cancer; 2004 Feb; 108(4):558-63. PubMed ID: 14696120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HLA-DRB1*0410-restricted recognition of XAGE-1b37-48 peptide by CD4 T cells.
    Morishita Y; Uenaka A; Kaya S; Sato S; Aji T; Nakayama E
    Microbiol Immunol; 2007; 51(8):755-62. PubMed ID: 17704638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Association of XAGE-1b gene expression with clinical characteristics of non-small cell lung cancer].
    Zhou Q; Guo AL; An SJ; Xu CR; Yang SQ; Wu YL
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jul; 27(7):966-8. PubMed ID: 17666327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors.
    Sato S; Noguchi Y; Ohara N; Uenaka A; Shimono M; Nakagawa K; Koizumi F; Ishida T; Yoshino T; Shiratori Y; Nakayama E
    Cancer Immun; 2007 Mar; 7():5. PubMed ID: 17335148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of preexisting humoral immunity specific for two cancer-testis antigens overexpressed at the mRNA level in non-small cell lung cancer.
    Watanabe Y; LePage S; Elliott M; Secrist H; Tanaka T; Kawahara M; Matsumura A; Hosoe S; Ogawara M; Okada M; Repasky B; Sleath P; Wang T; Henderson R
    Cancer Immun; 2006 Feb; 6():3. PubMed ID: 16468707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.
    Tsuji T; Altorki NK; Ritter G; Old LJ; Gnjatic S
    J Immunol; 2009 Oct; 183(7):4800-8. PubMed ID: 19734225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers.
    Egland KA; Kumar V; Duray P; Pastan I
    Mol Cancer Ther; 2002 May; 1(7):441-50. PubMed ID: 12479262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of tumor antigens and tumor-antigen specific T cells in NSCLC patients: Correlation of the quality of T cell responses with NSCLC subtype.
    Palata O; Podzimkova Hradilova N; Mysiková D; Kutna B; Mrazkova H; Lischke R; Spisek R; Adkins I
    Immunol Lett; 2020 Mar; 219():46-53. PubMed ID: 31931024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent T cell responses against immunogenic targets in lung cancer patients for targeted immunotherapy.
    Babiak A; Steinhauser M; Götz M; Herbst C; Döhner H; Greiner J
    Oncol Rep; 2014 Jan; 31(1):384-90. PubMed ID: 24154794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
    Iversen TZ
    Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.
    Saif JM; Vadakekolathu J; Rane SS; McDonald D; Ahmad M; Mathieu M; Pockley AG; Durrant L; Metheringham R; Rees RC; McArdle SE
    Eur J Immunol; 2014 Apr; 44(4):994-1004. PubMed ID: 24338683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.